Skylands Capital LLC Sells 63,500 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Skylands Capital LLC decreased its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 15.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 353,950 shares of the company's stock after selling 63,500 shares during the period. Skylands Capital LLC owned approximately 0.07% of Elanco Animal Health worth $5,274,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Handelsbanken Fonder AB grew its holdings in shares of Elanco Animal Health by 11.9% in the 4th quarter. Handelsbanken Fonder AB now owns 92,200 shares of the company's stock valued at $1,374,000 after buying an additional 9,800 shares during the period. Resonant Capital Advisors LLC boosted its stake in Elanco Animal Health by 19.3% in the 4th quarter. Resonant Capital Advisors LLC now owns 25,789 shares of the company's stock worth $384,000 after purchasing an additional 4,172 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Elanco Animal Health by 4.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 102,242 shares of the company's stock worth $1,523,000 after purchasing an additional 4,689 shares during the period. Phocas Financial Corp. acquired a new position in Elanco Animal Health in the 4th quarter worth $3,857,000. Finally, Smith Graham & Co. Investment Advisors LP boosted its stake in Elanco Animal Health by 16.0% in the 4th quarter. Smith Graham & Co. Investment Advisors LP now owns 322,497 shares of the company's stock worth $4,805,000 after purchasing an additional 44,527 shares during the period. Institutional investors and hedge funds own 97.48% of the company's stock.

Analysts Set New Price Targets

ELAN has been the subject of a number of research analyst reports. Morgan Stanley upped their target price on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 27th. TheStreet raised shares of Elanco Animal Health from a "d+" rating to a "c-" rating in a research note on Friday, February 23rd. Stifel Nicolaus upgraded shares of Elanco Animal Health from a "hold" rating to a "buy" rating and increased their price objective for the stock from $13.00 to $20.00 in a research note on Friday, January 5th. The Goldman Sachs Group increased their price objective on shares of Elanco Animal Health from $12.50 to $14.00 and gave the stock a "sell" rating in a research note on Tuesday, February 27th. Finally, Barclays increased their price objective on shares of Elanco Animal Health from $18.00 to $19.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, Elanco Animal Health presently has an average rating of "Moderate Buy" and an average target price of $16.71.

Elanco Animal Health Stock Performance

Shares of ELAN stock traded up $0.30 on Monday, reaching $13.57. The stock had a trading volume of 4,121,639 shares, compared to its average volume of 4,383,768. The company has a quick ratio of 1.35, a current ratio of 2.75 and a debt-to-equity ratio of 0.92. The firm's 50-day moving average is $15.31 and its two-hundred day moving average is $13.85. The firm has a market capitalization of $6.70 billion, a price-to-earnings ratio of -5.43, a P/E/G ratio of 1.39 and a beta of 1.29. Elanco Animal Health Incorporated has a 12 month low of $7.88 and a 12 month high of $16.88.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Monday, February 26th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.02). The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1 billion. Elanco Animal Health had a negative net margin of 27.87% and a positive return on equity of 6.44%. The firm's revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.19 earnings per share. On average, research analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Activity

In other news, Director R David Hoover bought 20,000 shares of the company's stock in a transaction dated Wednesday, March 6th. The shares were bought at an average cost of $16.14 per share, with a total value of $322,800.00. Following the acquisition, the director now owns 185,000 shares in the company, valued at $2,985,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.57% of the stock is owned by insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.